Refined By:
Author:  Al-Salami H.

Results 1-14 of 14 (Search time: 0.002 seconds).

Issue DateTitleAuthor(s)
11-Jan-2015An advanced microencapsulated system: A platform for optimized oral delivery of antidiabetic drug-bile acid formulationsMooranian A.; Negrulj R.; Mathavan S.; Martinez J.; Sciarretta J.; Chen-Tan N.; Mukkur T.; Momir Mikov ; Mladena Lalić-Popović ; Maja Stojančević; Svetlana Goločorbin-Kon ; Al-Salami H.
21-Jan-2007Bioavailability and hypoglycemic activity of the semisynthetic bile acid salt, sodium 3α,7α-dihydroxy-12-oxo-5β-cholanate, in healthy and diabetic ratsMomir Mikov ; Boni N.; Al-Salami H.; Ksenija Kuhajda; Slavko Kevresšan; Svetlana Goločorbin-Kon ; Fawcett J.
31-Jan-2019DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal ImpairmentMikov, Momir ; Pavlović, Nebojša ; Stanimirov, Bojan ; Đanić, Maja ; Goločorbin-Kon, Svetlana ; Stankov, Karmen ; Al-Salami H.
41-Jan-2019Formulation buoyancy of nanoencapsulated gliclazide using primary, conjugated and deconjugated bile acidsMathavan S.; Ionescu C.; Božica Kovačević; Momir Mikov ; Svetlana Goločorbin-Kon ; Mooranian A.; Dass C.; Al-Salami H.
59-Sep-2014Microencapsulation as a novel delivery method for the potential antidiabetic drug, ProbucolMooranian A.; Negrulj R.; Chen-Tan N.; Al-Sallami H.; Fang Z.; Mukkur T.; Momir Mikov ; Svetlana Goločorbin-Kon ; Fakhoury M.; Watts G.; Matthews V.; Arfuso F.; Al-Salami H.
628-Jul-2014Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A characterization studyMooranian A.; Negrulj R.; Chen-Tan N.; Al-Sallami H.; Fang Z.; Mukkur T.; Momir Mikov ; Svetlana Goločorbin-Kon ; Fakhoury M.; Arfuso F.; Al-Salami H.
71-Jan-2015Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro studyMooranian A.; Negrulj R.; Momir Mikov ; Svetlana Goločorbin-Kon ; Arfuso F.; Al-Salami H.
812-Nov-2018Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetesMooranian A.; Zamani N.; Takechi R.; Al-Sallami H.; Momir Mikov ; Svetlana Goločorbin-Kon ; Božica Kovačević; Arfuso F.; Al-Salami H.
91-Jan-2014Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 DiabetesMooranian A.; Negrulj R.; Al-Sallami H.; Fang Z.; Momir Mikov ; Svetlana Goločorbin-Kon ; Fakhoury M.; Watts G.; Matthews V.; Arfuso F.; Lambros A.; Al-Salami H.
101-Jan-2019Probucol-poly(meth)acrylate-bile acid nanoparticles increase IL-10, and primary bile acids in prediabetic miceMooranian A.; Zamani N.; Takechi R.; Al-Sallami H.; Momir Mikov ; Svetlana Goločorbin-Kon ; Božica Kovačević; Arfuso F.; Al-Salami H.
111-Jan-2015Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatmentMooranian A.; Negrulj R.; Al-Sallami H.; Fang Z.; Momir Mikov ; Svetlana Goločorbin-Kon ; Fakhoury M.; Aruso F.; Al-Salami H.
121-Feb-2019Stability and biological testing of taurine-conjugated bile acid antioxidant microcapsules for diabetes treatmentMooranian A.; Zamani N.; Momir Mikov ; Svetlana Goločorbin-Kon ; Goran Stojanović ; Arfuso F.; Al-Salami H.
131-Jan-2014Stability and release kinetics of an advanced gliclazide-cholic acid formulation: The Use of artificial-cell microencapsulation in slow release targeted oral delivery of antidiabeticsMooranian A.; Negrulj R.; Mathavan S.; Martinez J.; Sciarretta J.; Chen-Tan N.; Mukkur T.; Momir Mikov ; Mladena Lalić-Popović ; Maja Stojancěvić; Svetlana Goločorbin-Kon ; Al-Salami H.
143-Jul-2016Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetesNegrulj R.; Mooranian A.; Chen-Tan N.; Al-Sallami H.; Momir Mikov ; Svetlana Goločorbin-Kon ; Fakhoury M.; Watts G.; Arfuso F.; Al-Salami H.